^
    Back
    Association details:
    Biomarker:BRAF mutation + PD-L1 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy +
    BRAF inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    Molecular characteristics of BRAF mutated non-small cell lung cancer and therapeutic outcomes: Multi-institution study.

    Published date:
    05/19/2021
    Excerpt:
    BRAF mutant NSCLC is associated with high PD-L1 expression and responses to both checkpoint inhibitors and BRAF inhibitor combinations. Treatment with immunotherapy appears to have a superior toxicity profile and prolonged disease control in both BRAF V600E and non-V600E mutant NSCLC and is an effective first-line strategy.
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21029